SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil
A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer
3 other identifiers
interventional
75
1 country
86
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Ethynyluracil may help fluorouracil kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of fluorouracil plus ethynyluracil in treating patients with advanced colorectal cancer that has not responded to fluorouracil.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2 colorectal-cancer
Started Apr 1998
Longer than P75 for phase_2 colorectal-cancer
86 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 1998
CompletedFirst Submitted
Initial submission to the registry
November 1, 1999
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2002
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2003
CompletedFirst Posted
Study publicly available on registry
June 16, 2004
CompletedMarch 8, 2012
March 1, 2012
4.6 years
November 1, 1999
March 6, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Confirmed Response Rate
To assess the confirmed response rate to 5-fluorouracil plus 776C85 in patients with measurable, disseminated colorectal cancer that has been demonstrated to be resistant to 5-fluorouracil.
Once every 10 weeks until off treatment
Secondary Outcomes (2)
Progression and Survival
Once every 10 weeks until progression
Toxicities
Once each week during treatment
Study Arms (1)
776C85 + 5-FU
EXPERIMENTAL776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- SWOG Cancer Research Networklead
- National Cancer Institute (NCI)collaborator
Study Sites (86)
MBCCOP - University of South Alabama
Mobile, Alabama, 36688, United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726, United States
Veterans Affairs Medical Center - Phoenix (Hayden)
Phoenix, Arizona, 85012, United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723, United States
Arizona Cancer Center
Tucson, Arizona, 85724, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205, United States
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800, United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781, United States
Beckman Research Institute, City of Hope
Los Angeles, California, 91010, United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305, United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
University of California Davis Medical Center
Sacramento, California, 95817, United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128, United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403, United States
David Grant Medical Center
Travis Air Force Base, California, 94535, United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220, United States
University of Colorado Cancer Center
Denver, Colorado, 80262, United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701, United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650, United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813, United States
Tripler Army Medical Center
Honolulu, Hawaii, 96859-5000, United States
CCOP - Central Illinois
Decatur, Illinois, 62526, United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141, United States
Loyola University Medical Center
Maywood, Illinois, 60153, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7357, United States
CCOP - Wichita
Wichita, Kansas, 67214-3882, United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218, United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093, United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084, United States
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112, United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112, United States
Veterans Affairs Medical Center - New Orleans
New Orleans, Louisiana, 70112, United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932, United States
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130, United States
Boston Medical Center
Boston, Massachusetts, 02118, United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130, United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752, United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503, United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975, United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410, United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505, United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216, United States
Keesler Medical Center - Keesler AFB
Keesler Air Force Base, Mississippi, 39534-2576, United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128, United States
CCOP - Kansas City
Kansas City, Missouri, 64131, United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807, United States
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250, United States
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141, United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101, United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138, United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131, United States
Veterans Affairs Medical Center - Brooklyn
Brooklyn, New York, 11209, United States
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45219, United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288, United States
Cleveland Clinic Cancer Center
Cleveland, Ohio, 44195, United States
CCOP - Columbus
Columbus, Ohio, 43206, United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428, United States
CCOP - Dayton
Kettering, Ohio, 45429, United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104, United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104, United States
Oregon Cancer Center at Oregon Health Sciences University
Portland, Oregon, 97201-3098, United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207, United States
CCOP - Columbia River Program
Portland, Oregon, 97213, United States
CCOP - Greenville
Greenville, South Carolina, 29615, United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303, United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234, United States
University of Texas Medical Branch
Galveston, Texas, 77555-1329, United States
Texas Tech University Health Science Center
Lubbock, Texas, 79423, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7811, United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284, United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504, United States
CCOP - Scott and White Hospital
Temple, Texas, 76508, United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84132, United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148, United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101, United States
Swedish Cancer Institute
Seattle, Washington, 98104, United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108, United States
CCOP - Northwest
Tacoma, Washington, 98405-0986, United States
Related Publications (1)
Leichman CG, Chansky K, Macdonald JS, Doukas MA, Budd GT, Giguere JK, Abbruzzese JL; Southwest Oncology Group. Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. Invest New Drugs. 2002 Nov;20(4):419-24. doi: 10.1023/a:1020662113061.
PMID: 12448660RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Cynthia G. Leichman, MD
Albany Medical College
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 1, 1999
First Posted
June 16, 2004
Study Start
April 1, 1998
Primary Completion
November 1, 2002
Study Completion
October 1, 2003
Last Updated
March 8, 2012
Record last verified: 2012-03